Edition:
United Kingdom

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

9.55USD
21 Aug 2018
Change (% chg)

$-0.09 (-0.93%)
Prev Close
$9.64
Open
$9.69
Day's High
$9.69
Day's Low
$9.39
Volume
69,982
Avg. Vol
236,713
52-wk High
$31.42
52-wk Low
$6.99

Select another date:

Fri, Jun 29 2018

Photo

FDA approves Dermira's wipe for excessive armpit sweating

Dermira Inc said on Friday its topical cloth for excessive armpit sweating was approved by the U.S. Food and Drug Administration, providing patients with an easy-to-use option for an often embarrassing condition.

UPDATE 2-FDA approves Dermira's wipe for excessive armpit sweating

* Qbrexza expected to launch in October (Adds analyst comment, estimates; updates share move)

Dermira's treatment for excessive armpit sweating gets U.S. approval

June 29 The U.S. Food and Drug Administration on Friday approved Dermira Inc's treatment for excessive armpit sweating, providing patients with an easy-to-use treatment option for an often embarrassing condition.

BRIEF-Dermira Says Company's COO Position Was Eliminated

* DERMIRA SAYS COMPANY'S CHIEF OPERATING OFFICER POSITION WAS ELIMINATED, EFFECTIVE AS OF MAY 3, 2018 - SEC FILING Source : https://bit.ly/2Iesp3E Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Dermira Inc Q1 Loss Per Share $1.42

* DERMIRA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Dermira to abandon acne drug, shares crater

Dermira Inc will discontinue development of its acne drug after the treatment failed to meet the main goals of two late-stage studies, the company said on Monday.

UPDATE 2-Dermira to abandon acne drug, shares crater

* Drug results not to affect two other programs - company (Adds conference call details, analyst comment, updates share price)

Dermira abandons acne drug

March 5 Dermira Inc said on Monday it would discontinue the development of its acne drug after it failed to meet the main goals of two late-stage studies.

BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints

* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS

BRIEF-Dermira Qtrly Loss Per Share $‍1.34​

* DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Select another date: